Clinical Scorecard: Cross-Site Evaluation of Cardiometabolic Diagnoses in Young Individuals with Congenital Adrenal Hyperplasia: Insights from a PEDSnet Study
Genetic enzyme deficiency leading to cortisol and aldosterone deficiency, excess androgen secretion, and disrupted adrenal steroidogenesis
Target Population
Youth with CAH, including classic and nonclassic forms
Care Setting
Pediatric outpatient clinical settings within large health systems
Key Highlights
Youth with CAH have significantly increased odds of overweight/obesity, hypertension, dysglycemia, dyslipidemia, and liver dysfunction compared to matched controls.
Classic CAH patients show especially high odds of hypertension and liver dysfunction alongside overweight/obesity.
Cardiometabolic comorbidities in CAH begin in childhood and adolescence, underscoring early risk.
Guideline-Based Recommendations
Diagnosis
Identify CAH via clinical diagnosis codes and confirm classic CAH by presence of glucocorticoid and mineralocorticoid prescriptions.
Use electronic health record data for longitudinal monitoring of cardiometabolic diagnoses.
Management
Treat classic CAH with glucocorticoid and mineralocorticoid replacement to correct hormone deficiencies and reduce androgen excess.
Monitor and manage cardiometabolic risk factors including obesity, hypertension, dysglycemia, and dyslipidemia.
Monitoring & Follow-up
Regular assessment of anthropometric measures, blood pressure, glucose metabolism, lipid profiles, and liver function.
Evaluate medication use including antihypertensives, lipid-lowering, and glucose-regulating agents.
Risks
Increased risk of early-onset overweight/obesity and hypertension in youth with CAH.
Potential adverse metabolic and cardiovascular outcomes due to fluctuating cortisol levels from imperfect glucocorticoid replacement.
Cardiovascular disease is a leading cause of death after adrenal crisis in CAH.
Patient & Prescribing Data
Youth with classic CAH identified by glucocorticoid and mineralocorticoid prescriptions
Glucocorticoid and mineralocorticoid therapy is essential for classic CAH; monitoring for cardiometabolic medication use is important due to increased comorbidity risk.
Clinical Best Practices
Use propensity score matching to compare CAH patients with controls for accurate risk assessment.
Employ multisite electronic health record data to capture large, diverse pediatric populations.
Focus on early identification and management of cardiometabolic risk factors in CAH youth to improve long-term outcomes.
by Li-Min Chen, Anna Valentine, Shanlee M Davis, Evan Graber, Patricia Y Fechner, Anna Furniss, Leena Nahata, Laura Pyle, Arpita K Vyas, Maria G Vogiatzi, Natalie J Nokoff
